Allogeneic T cell progenitors, cultured ex-vivo for Acute Leukemia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Acute LeukemiaAllogeneic T cell progenitors, cultured ex-vivo - Biological
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a new treatment can help people with relapsed or refractory leukemia by increasing the speed of immune system recovery after a stem cell transplant.

Eligible Conditions
  • Acute Leukemia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
αβ-TCR/CD19 cell depleted haploidentical hematopoietic stem cell graft
1
UCART19 follow-up
1
T-allo10

Study Objectives

3 Primary · 3 Secondary · Reporting Duration: Month 24 post-HSCT

100 days post-HSCT
CD4+ T cell count
Cumulative incidence of grade III-IV GvHD
Occurrence of adverse events related to SMART101
Month 6
Communicable Diseases
Non-relapse mortality (NRM)
Month 24 post-HSCT
Disease-free Survival
Overall Survival (OS)
Month 12
T cell immune reconstitution

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
αβ-TCR/CD19 cell depleted haploidentical hematopoietic stem cell graft
1
UCART19 follow-up
1
T-allo10

Trial Design

2 Treatment Groups

Pediatric patients affected by acute leukemia (AML, ALL)
1 of 2
Adult patients affected by acute leukemia (AML, ALL)
1 of 2

Experimental Treatment

36 Total Participants · 2 Treatment Groups

Primary Treatment: Allogeneic T cell progenitors, cultured ex-vivo · No Placebo Group · Phase 1 & 2

Pediatric patients affected by acute leukemia (AML, ALL)
Biological
Experimental Group · 1 Intervention: Allogeneic T cell progenitors, cultured ex-vivo · Intervention Types: Biological
Adult patients affected by acute leukemia (AML, ALL)
Biological
Experimental Group · 1 Intervention: Allogeneic T cell progenitors, cultured ex-vivo · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: month 24 post-hsct

Who is running the clinical trial?

Smart Immune SASLead Sponsor
1 Previous Clinical Trials
8 Total Patients Enrolled
Jaap-Jan BOELENS, MD, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center (MSKCC)

Eligibility Criteria

Age Any Age · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
High risk in CR1; Philadelphia (like) or any poor risk feature.
You are eligible for an allogeneic HSCT.
You are aged 21 years or older and have a clinical condition compatible with allogeneic bone marrow transplantation.
You have a Karnofsky index of 70% or higher.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top